Open-label phase II trial of recombinant beta interferon (IFN-beta (ser)) in patients with colorectal cancer.
Triozzi
P L
PL
Department of Internal Medicine, Ohio State University Comprehensive Cancer Center, Columbus.
Kenney
P
P
Young
D
D
Rinehart
J J
JJ
D000328:Adult; D000368:Aged; D002986:Clinical Trials as Topic; D003110:Colonic Neoplasms / Q000628:therapy*; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007370:Interferon Type I / Q000009:adverse effects / Q000627:therapeutic use*; D000068556:Interferon beta-1a; D000068576:Interferon beta-1b; D016899:Interferon-beta; D008113:Liver Neoplasms / Q000556:secondary; D008297:Male; D008875:Middle Aged; D011994:Recombinant Proteins / Q000009:adverse effects / Q000627:therapeutic use*; D012004:Rectal Neoplasms / Q000628:therapy*
D007370:Interferon Type I; D011994:Recombinant Proteins; D000068576:Interferon beta-1b; D016899:Interferon-beta; D000068556:Interferon beta-1a